 This is a Phase 2, non-randomized study of neoadjuvant treatment with nanoparticle albumin bound paclitaxel Abraxane every week for 12 weeks followed by 5-FU, epirubicin, and cyclophosphamide FEC every 3 weeks for 4 cycles in women with locally advanced breast cancer. Patients with HER-2 overexpressing breast cancer may receive trastuzumab concurrently with the chemotherapy at the discretion of the investigator. The primary aim of this study is to determine the pathologic complete response rate pCR of this sequential regimen. 